Skip to main content

211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation

Publication ,  Journal Article
Larsen, RH; Murud, KM; Akabani, G; Hoff, P; Bruland, ØS; Zalutsky, MR
Published in: Journal of Nuclear Medicine
1999

Bisphosphonates were synthesized for use as carriers for astatine and iodine radioisotopes to target bone neoplasms. Methods: Radiohalogenated activated esters were coupled to the amino group in the side chain of the bisphosphonate. The bisphosphonate 3-amino-1-hydroxypropylidene bisphosphonate was combined with four different acylation agents: N- succinimidyl 3-[211At]astatobenzoate, N-succinimidyl 3- [131I]iodobenzoate, N-succinimidyl-5-[211At]astato-3-pyddinecarboxylate and N-succinimidyl-5-[131I]iodo-5-pyridinecarboxylate. The products, 3- [131I]iodobenzamide-N-3-hydroxypropylidene-3,3-bisphosphonate (IBPB), 3- [211At]astato-benzamide-N-3-hydroxypropylidene-3,3-bisphosphonate (ABPB), 5-[131I]iodopyridine-3-amide-N-3-hydroxypropylidene-3,3-bisphosphonate (IPPB) and 5-[211At]astatopyridine-3-amide-N-3-hydroxypropylidene-3,3- bisphosphonate (APPB), were injected intravenously into Balb/c mice. MIRD and Monte Carlo methods were used on the basis of cumulated activity calculated from biodistribution data to estimate dose to organs and bone segments. Results: All 131I- and 211At-labeled analogs were strongly incorporated into osseous tissue and retained there at stable levels, while a rapid clearance from blood was observed. The bone uptake was found to be similar for 211At- and 131I-labeled bisphosphonate when compared in paired label experiments, Bone uptake and bone-to-tissue ratios were better for IBPB compared with IPPB, and ABPB compared with APPB. All four compounds appeared to be highly resistant to in vivo dehalogenation as indicated by low uptake of 131I/211At in the thyroid gland and stomach. According to dosimetric estimates, the bone surface-to-bone marrow ratio was three times higher with 211At than with 131I. Conclusion: Both the β-particle- and α- particle-emitting compounds showed high in vivo stability and excellent affinity for osseous tissue. Further preclinical evaluation is therefore warranted.

Duke Scholars

Published In

Journal of Nuclear Medicine

Publication Date

1999

Volume

40

Issue

7

Start / End Page

1197 / 1203

Related Subject Headings

  • Nuclear Medicine & Medical Imaging
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Larsen, R. H., Murud, K. M., Akabani, G., Hoff, P., Bruland, Ø. S., & Zalutsky, M. R. (1999). 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. Journal of Nuclear Medicine, 40(7), 1197–1203.
Larsen, R. H., K. M. Murud, G. Akabani, P. Hoff, Ø. S. Bruland, and M. R. Zalutsky. “211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.” Journal of Nuclear Medicine 40, no. 7 (1999): 1197–1203.
Larsen RH, Murud KM, Akabani G, Hoff P, Bruland ØS, Zalutsky MR. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. Journal of Nuclear Medicine. 1999;40(7):1197–203.
Larsen, R. H., et al. “211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.” Journal of Nuclear Medicine, vol. 40, no. 7, 1999, pp. 1197–203.
Larsen RH, Murud KM, Akabani G, Hoff P, Bruland ØS, Zalutsky MR. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. Journal of Nuclear Medicine. 1999;40(7):1197–1203.

Published In

Journal of Nuclear Medicine

Publication Date

1999

Volume

40

Issue

7

Start / End Page

1197 / 1203

Related Subject Headings

  • Nuclear Medicine & Medical Imaging
  • 1103 Clinical Sciences